and PD-L1 constitute a key pathway in local tumor immunosuppression, and inhibition of the PD-1-PD-L1 axis has been reported to be an effective therapy for various malignancies. [3] [4] [5] [6] Expression of PD-L1 in tumor cells is regulated by several extrinsic and intrinsic factors. 7, 8 In particular, γ-interferon (IFN-γ) in the tumor microenvironment has been reported to be a key extrinsic regulator of PD-L1 expression. IFN-γ principally activates JAK and STAT signaling pathways, which induce the direct binding of its transcription factor, IFN regulatory factor 1, to the promoter region of PD-L1. [3] [4] [5] 9 However, expression of PD-L1 by IFN-γ stimulation is mediated by multiple mechanisms. In medulloblastomas, IFN-γ induces PD-L1 upregulation, which is required for the supportive effect of cyclin-dependent kinase 5.
10
CD74, also known as MHC class II-associated invariant chain, is a type II transmembrane glycoprotein. 11 Part of this glycoprotein is exposed on the cell surface and functions as a receptor for macrophage migration inhibitory factor (MIF). [12] [13] [14] The MIF-CD74 interactions induce activation of RAS-RAF-MEK-ERK MAPK signaling and the PI3K-AKT signaling pathway. 14, 15 Stimulation of IFN-γ has also been reported to upregulate the expression of CD74. 16 In a previous analysis of melanoma patient samples, serum IFN-γ levels and CD74 expression levels in tumor cells showed a significant correlation. In addition, treating melanoma cell lines with recombinant IFN-γ protein resulted in upregulation of cell surface CD74 protein levels. 17 Based on these findings that IFN-γ stimulation upregulates expression levels of both CD74 and PD-L1, we hypothesized that expression of PD-L1 is mediated by MIF-CD74 interactions. Here we showed a significant association between the expression levels of PD-L1 and MIF-CD74 interactions.
| MATERIAL S AND ME THODS

| Patients and tumor samples
The 
| Immunohistochemical and immunocytochemical analyses
| Cell lines and reagents
The human melanoma A375 cell line was obtained from ATCC 
| Cell counting and cell viability assay
| Antibodies and western blot analysis
Mouse monoclonal anti-human CD74 Ab (LN2; Santa Cruz The membranes were incubated with ECL immunoblotting detection reagent followed by exposure to hyperfilm (GE Healthcare).
| Flow cytometry analysis
Melanoma cells (1 × 10 6 ) were allowed to grow in medium with or without IFN-γ (100 IU/mL) or 4-IPP for 48 hours. 
| Focused protein array
The expression status of proteins in each lysate was measured using a human phospho-kinase array kit (Proteome Profiler; Lysates were applied to a human phosphor-kinase array kit according to the manufacturer's protocol. Protein expression dots were scanned using a computer scanner, and dot pixel density was quantified with Photoshop CS5.1 software (Adobe, San Jose, CA, USA).
| Statistical analysis
To assess the correlation between the expression levels of CD74 and PD-L1 by immunohistochemistry, Fisher's exact tests were applied.
For all in vitro experiments, statistical analyses were carried out using Student's t test. All P values were 2-sided, and a value of P < .05 was considered statistically significant. All statistical analyses were performed using Excel software (Microsoft, Redmond, WA, USA).
| RE SULTS
| Significant correlation between CD74 and PD-L1 expression in melanoma tissue samples
To examine the CD74 and PD-L1 expression levels in melanoma tissue samples, we undertook immunohistochemical staining in 97 melanoma samples obtained from 70 patients (patient characteristics are summarized in Table 1 We then analyzed the correlation between the expression levels of CD74 and PD-L1, which showed significant correlations in all 97
analyzed samples (χ 2 , 12.44; P < .01), and in 64 primary tumor samples (χ 2 , 13.97; P < .01) and 33 metastatic tumor samples (χ 2 , 9.03; P < .01) ( Figure 1B ). In the further analysis evaluating expression of each sample as positive by the percentage of melanoma cells with positive staining (CD74 >50%, PD-L1 >50%), increased percentage of PD-L1 expression was significantly correlated with that in CD74 expression (P < .01; Figure S1B ). In the correlation analysis between those expression levels and tumor progression, PD-L1 positivity significantly correlated with tumor progression (P < .05; Figure S1C ).
| Upregulated expression of CD74 by IFN-γ stimulation
On the basis of previous findings that IFN-γ upregulates both PD-L1 and cell surface CD74 expression, 17 we hypothesized that 
| Upregulated expression of PD-L1 by IFN-γ stimulation suppressed by inhibition of MIF-CD74 interaction
Next we evaluated the expression levels of PD-L1 under IFN-γ and/ or 4-IPP treated conditions. Expression of PD-L1 was negative in both cell lines under normal culture conditions, but was dramati- 
| D ISCUSS I ON
Melanoma is the most aggressive form of skin cancer and is believed to have a highly immunogenic potential. Recent advances in therapy have provided immune checkpoint inhibitors that show impressive clinical benefits in patients with metastatic melanoma. [18] [19] [20] [21] However, blockade of the PD-1-PD-L1 interaction does not induce tumor regression in all patients. 20, 21 Further understanding of the molecular mechanisms underlying immune evasion of cancers, as well as the mechanisms for controlling PD-L1 expression, will therefore be important in improving the efficacy of antitumor immunotherapy.
In the present study, we showed that the MIF-CD74 interaction Expression of PD-L1 is regulated by several genomic, epigenetic, and transcriptional mechanisms. 7, 8 Genomic rearrangements, including gene amplification and translocation in chromosomes, have been reported to upregulate PD-L1 expression in several malignancies. [22] [23] [24] Epigenetically, bromodomain-containing protein 4 25, 26 and histone methyltransferase MLL1 have been associated with the expression of PD-L1. 27 Regarding its regulation at the transcriptional level, various signaling pathways, including the JAK-STAT, 5 NF-κB, 28 MAPK, and PI3K-AKT signaling pathways 29, 30 CD74 has dual functional roles. It has usually been identified as a chaperone of MHC class II Dα and Dβ chains, 33 but a small proportion of CD74 is found on the cell surface independent of the MHC class II complex, 12 where it functions as a receptor for MIF. 12-14 CD74
F I G U R E 6 Schematic image of this study. γ-Interferon (IFN-γ) stimulation upregulates expression levels of programmed cell death ligand 1 (PD-L1) mediated by the activation of macrophage migration inhibitory factor (MIF)-CD74 interactions, which is induced by the upregulation of cell surface CD74 expression by IFN-γ stimulation has been reported to be expressed in various malignancies and serves as a prognostic factor, disease progression marker, and promoter of invasion and metastasis. 17, [34] [35] [36] [37] [38] with the invasiveness and metastatic potential of tumor cells. 42, 43 Additionally, secretion of both IL-6 and IL-8 from tumor cells has been reported to enrich the Foxp3 + CD4-regulatory T-cell subset among T cells migrating toward melanoma, thereby creating an immunosuppressive microenvironment. 44 Together with its regulatory role in PD-L1 expression in tumor cells, activation of the MIF-CD74 interaction plays a critical role in melanoma cells by causing immune evasion and promoting survival in the microenvironment of the antitumorigenic immune reaction.
In conclusion, MIF-CD74 interaction is a regulator of PD-L1 expression and plays a key role in maintaining an advantageous tumor microenvironment for tumor cells. The MIF-CD74 interaction is therefore a possible target for effective treatment of melanoma patients.
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